SCHEMBL742165

SCHEMBL742165

CCCCCc1ccc(-c2ccc(C(=O)Oc3ccc(CC(C)CC)cc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
RARB P10826 6/20 0.52
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
RARA P10276 1/20 0.51
MTOR P42345 1/20 0.51
KMT2A Q03164 1/20 0.51
THRB P10828 4/20 0.49
THRA P10827 1/20 0.47
PPARA Q07869 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11547790 1.00 MAPT (0.55) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL20594587 1.00 MAPT (0.55) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL20594622 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL9434739 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL10746703 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL29359854 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL9185134 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL20594559 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL5065172 0.99 MAPT (0.54) MAPTSMN1; SMN2RARBMEN1ALDH1A1
SCHEMBL8955924 0.96 RARB (0.51) MAPTSMN1; SMN2RARBMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299675-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2022-04-12 US disclosed
US-11193066-B2 Polymerizable compound and composition, liquid crystal composite, optical anisotropic body, liquid crystal display device and use thereof JNC CORPORATION (JP) 2021-12-07 US disclosed
US-10975305-B2 Piperidine derivative, liquid crystal composition, and liquid crystal display element JNC CORPORATION (JP) 2021-04-13 US disclosed
US-20210071080-A1 COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2021-03-11 US disclosed
US-10787608-B2 Liquid crystal display device including liquid crystal medium containing low molecular weight polar compound for homogeneously aligning liquid crystal medium JNC CORPORATION (JP) 2020-09-29 US disclosed
US-20200299578-A1 POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2020-09-24 US disclosed
US-10759998-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display element JNC CORPORATION (JP) 2020-09-01 US disclosed
EP-3305774-B1 BENZOTHIOPHENE-CONTAINING LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORP (JP) 2020-08-26 EP disclosed
US-20200263089-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2020-08-20 US disclosed
US-20200239775-A1 TETRACYCLIC LIQUID CRYSTAL COMPOUND HAVING DIATOMIC BONDING GROUP AND 2,3-DIFLUOROPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2020-07-30 US disclosed
US-20070187644-A1 Liquid crystal compound, liquid crystal composition, and liquid crystal display device JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) 2007-08-16 US disclosed
EP-1818384-A1 Liquid crystal compound, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2007-08-15 EP disclosed
US-7247355-B2 Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition CHISSO CORPORATION (JP) 2007-07-24 US disclosed
US-7247355-B2 Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition CHISSO CORPORATION (JP) 2007-07-24 US disclosed
EP-1798228-A1 TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAYS CONTAINING THE COMPOSITIONS CHISSO CORPORATION (JP) 2007-06-20 EP disclosed
US-20070108410-A1 Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION 2007-05-17 US disclosed
US-20070108410-A1 Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION 2007-05-17 US disclosed
EP-1762605-A1 Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition Chisso Petrochemial Corporation (JP) 2007-03-14 EP disclosed
US-20070051919-A1 NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION CHISSO PETROCHEMICAL CORPORATION (JP) 2007-03-08 US disclosed
US-20070051919-A1 NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION CHISSO PETROCHEMICAL CORPORATION (JP) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070051919-A1 NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION LEF1, CFD, FOXO1 MAPT 3479/4885SMN1; SMN2 2411/4885RARB 4017/4885
US-11193066-B2 Polymerizable compound and composition, liquid crystal composite, optical anisotropic body, liquid crystal display device and use thereof OCIAD2, PYM1, C1S MAPT 1096/4885SMN1; SMN2 2325/4885RARB 2346/4885
US-10787608-B2 Liquid crystal display device including liquid crystal medium containing low molecular weight polar compound for homogeneously aligning liquid crystal medium ACP1, MAPK1, PLD1 MAPT 1536/4885SMN1; SMN2 3758/4885RARB 3543/4885
US-20070108410-A1 Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device TCF7L2, TCF7, CA7 MAPT 3573/4885SMN1; SMN2 4751/4885RARB 245/4885
US-10759998-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display element SP1, SFXN3, SFXN1 MAPT 1879/4885SMN1; SMN2 2234/4885RARB 3235/4885
US-20200299578-A1 POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, CCND1, CPNE4 MAPT 2337/4885SMN1; SMN2 3491/4885RARB 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.